Shopping Cart
- Remove All
- Your shopping cart is currently empty
Mitazalimab (ADC-1013) is a monoclonal IgG antibody targeting CD40 and a CD40 agonist with antitumor activity. Mitazalimab activates antigen-presenting cells, induces transient peripheral transcriptome changes, and can be used to study tumors.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $247 | In Stock | |
5 mg | $645 | In Stock | |
10 mg | $987 | In Stock | |
25 mg | $1,530 | In Stock | |
50 mg | $1,980 | In Stock | |
100 mg | $2,790 | In Stock |
Description | Mitazalimab (ADC-1013) is a monoclonal IgG antibody targeting CD40 and a CD40 agonist with antitumor activity. Mitazalimab activates antigen-presenting cells, induces transient peripheral transcriptome changes, and can be used to study tumors. |
In vitro | Mitazalimab (1 ng/mL-10 μg/mL) was able to activate tumor-associated macrophages (TAM) in human prostate or ovarian cancer samples. [2] |
In vivo | Mitazalimab (100 μg/mouse, intraperitoneal injection, single dose) was able to activate splenic dendritic cells and B-cells in naïve hCD40tg mice and induced OVA-specific CD8+ T-cell expansion under OVA reprocessing conditions (200 μg intravenously, 3 times over 7 consecutive days). In addition, Mitazalimab (100 and 300 μg/mouse, intraperitoneal injection, administered on days 7, 10, and 13 post-inoculation) induced the release of pro-inflammatory cytokines and chemokines in the blood of animals bearing bladder tumors in MB49 mice and affected the composition of tumor bone marrow cells, resulting in a decrease in monocytes and macrophages and an increase in the number of granulocytes. [1] |
Alias | JNJ7107, JNJ-64457107, JNJ64457107, JNJ 7107, ADC-1013, AD-1013 |
Cas No. | 2055640-86-1 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.